Clinical Trial Update: Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated the safety and potential effectiveness of autologous HIV-specific CD8+ T cells in adults with HIV. The trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Autologous HIV-specific CD8+ T cell immunotherapy (HIV-specific CD8+ T cells)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED